GKIM
CTSO icon

GW&K Investment Management’s Cytosorbents Corp CTSO Stock Holding History

GW&K Investment Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed – – 506
2022
Q4 		$0 Buy
+30
New +$45 ﹤0.01% 464

Other funds holding CTSO

SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

GW&K Investment Management's CTSO Position: Q1 2023 in Review

GW&K Investment Management sold out of Cytosorbents Corp (CTSO) in Q1 2023, closing a stake of 30 shares.

GW&K Investment Management first reported a position in CTSO in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 59 funds tracked by Wall St. Rank hold CTSO as of Q1 2023.

  • GW&K Investment Management reported no remaining Cytosorbents Corp position as of Q1 2023 after selling out during the quarter.
  • GW&K Investment Management sold 30 Cytosorbents Corp shares in Q1 2023.
  • GW&K Investment Management first reported a position in Cytosorbents Corp in Q4 2022 and held it in 1 quarter.
  • GW&K Investment Management's Cytosorbents Corp position peaked at $0 in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2023.

Based on GW&K Investment Management's 13F filing for Q1 2023, filed 9 May 2023.